Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

NCT05502341 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

689

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Bictegravir
DRUG: Lenacapavir
DRUG: BIC/LEN FDC
DRUG: Stable Baseline Regimen

Sponsor

Gilead Sciences